We compared the efficacy of first-generation EGFR-TKIs combined with low-dose bevacizumab versus osimertinib monotherapy in untreated patients with advanced EGFR-mutated NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.